학술논문
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Document Type
Article
Author
Winer, Eric P ; Lipatov, Oleg; Im, Seock-Ah; Goncalves, Anthony; Muñoz-Couselo, Eva; Lee, Keun Seok; Schmid, Peter; Tamura, Kenji; Testa, Laura; Witzel, Isabell; Ohtani, Shoichiro; Turner, Nicholas; Zambelli, Stefania; Harbeck, Nadia; Andre, Fabrice; Dent, Rebecca; Zhou, Xuan; Karantza, Vassiliki; Mejia, Jaime; Cortes, Javier
Source
In The Lancet Oncology April 2021 22(4):499-511
Subject
Language
ISSN
1470-2045